AstraZeneca (LSE:AZN) and Amgen have reported positive Phase III results for Tezspire, with the biologic achieving statistically significant and clinically meaningful improvements across all primary and key secondary endpoints in patients with eosinophilic esophagitis.
Results from the Phase III CROSSING trial showed improvements in both histologic remission and difficulty swallowing, with the benefits maintained through week 52. Tezspire’s safety profile was also consistent with its established use in severe asthma and chronic rhinosinusitis with nasal polyps.
The successful trial represents Tezspire’s third positive outcome in an epithelial-driven inflammatory disease, reinforcing its potential to address a broader range of immune-mediated conditions.
The findings could provide AstraZeneca with an additional growth opportunity in respiratory and immunology, particularly given the limited effective treatment options currently available for eosinophilic esophagitis. The results also support Tezspire’s potential in this orphan disease indication.
Beyond eosinophilic esophagitis, AstraZeneca and Amgen continue to explore the therapy’s wider potential, including through ongoing Phase III studies in chronic obstructive pulmonary disease.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company with an established presence in respiratory and immunology medicines. Its portfolio includes biologic treatments such as monoclonal antibodies designed to address chronic inflammatory and immune-mediated diseases.
Building on its long-standing respiratory franchise, the company continues to expand into conditions where patients face significant unmet medical needs and where targeted biologic therapies could provide new treatment options.
Leave a Reply